Aditxt, Inc. (ADTX) — SEC Financial Statements & Analysis

Aditxt, Inc. (ADTX) is a pharmaceutical preparations company, incorporated in DE. Aditxt, Inc. trades on Nasdaq as: ADTX. Aditxt, Inc. (ADTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-20. Based on that filing, Aditxt, Inc. carries a market cap of $533.26K, a P/E ratio of -0.01x, a P/B ratio of -0.02x, a P/S ratio of 37.20x, an enterprise value of $3.57M, and an EV/EBITDA multiple of -0.20x. On profitability, it posts a gross margin of 19.89%, an operating margin of -127821.37%, a net margin of -372062.41%, a Return on Equity (ROE) of 660.16%, a Return on Assets (ROA) of -236.38%, and a Return on Invested Capital (ROIC) of -394.92%. Per share, it reports EPS of $-2643.94, diluted EPS of $-2643.94, free cash flow per share of $-920.20, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -74.09% year-over-year, net income growth of 105.14% year-over-year, and EPS growth of 194.89% year-over-year. On the balance sheet, it maintains a current ratio of 0.06x, a quick ratio of 0.02x, working capital of $-12.49M, a debt-to-equity ratio of -1.47x, a debt ratio of 3.53, an interest coverage ratio of -33.27x, free cash flow of $-18.56M (TTM), and net debt of $3.04M. Figures sourced from SEC EDGAR.

Market Cap

$533.26K

P/E TTM

-0.01x

EPS TTM

$-2643.94

P/B TTM

-0.02x

ROE TTM

660.16%

ROA TTM

-236.38%

Debt To Equity

-1.47x

Free Cash Flow TTM

$-18.56M

Net Revenue TTM Growth 1Y

-74.09%

Data as of 2026-03-31 · Source: SEC EDGAR